Technology transfer / Localization · MENA · Announced 30 Jun 2026
Novo Nordisk Algérie → Groupe Saidal
Novo Nordisk Algérie and Saidal signed a contract to jointly produce and distribute GLP-1-based treatments for type 2 diabetes and metabolic syndromes in Algeria. Products and terms were not disclosed.
Parties: Novo Nordisk Algérie (Algeria) → Groupe Saidal (Algeria)
- Deal type
- Technology transfer / Localization
- Value
- Undisclosed
- Territory
- Algeria
- Therapeutic area
- Metabolic / Diabetes
- Asset
- GLP-1-based molecules (not named)
- Announced
- 30 Jun 2026
Our analysis
Why this matters
Saidal and Novo Nordisk Algérie signed a contract on 30 June 2026 for the joint production and distribution in Algeria of innovative GLP-1-based treatments for adults with type 2 diabetes and metabolic syndromes. Saidal CEO Mourad Belkhelfa and Novo Nordisk Algérie general manager Amine Dahaoui signed at Novo Nordisk Algérie's headquarters. The contract extends an existing strategic partnership between the two companies. No molecules, site, volumes, timelines or value were disclosed.
GLP-1 medicines are among the most supply-constrained and highest-value products in the market, so putting them into a local production and distribution agreement is significant. Our reading is that Algeria is using its localization policy to secure supply of a class for which global demand exceeds capacity.
The full analysis is free to read with a work email on this page.
Source: Algérie Eco